Nuclear HMGB1 protects from non-alcoholic fatty liver diseases through negative regulation of liver X receptor
Personnaz, J.; Piccolo, E.; Dortignac, A.; Iacovoni, J. S.; Mariette, J.; Polizzi, A.; Batut, A.; Deleruyelle, S.; Paccoud, R.; Moreau, E.; Martins, F.; Clouaire, T.; Benhamed, F.; Montagner, A.; Wahli, W. A.; Schwabe, R. F.; Yart, A.; Castan-Laurell, I.; Postic, C.; Moro, C.; Legube, G.; Lee, C.-H.; Guillou, H.; Valet, P.; Dray, C.; Pradere, J.-P.
Show abstract
Dysregulations of lipid metabolism in the liver may trigger steatosis progression leading to potentially severe clinical consequences such as non-alcoholic fatty liver diseases (NAFLD). Molecular mechanisms underlying liver lipogenesis are very complex and fine-tuned by chromatin dynamics and the activity of multiple key transcription factors. Here, we demonstrate that the nuclear factor HMGB1 acts as a strong repressor of liver lipogenesis during metabolic stress in NAFLD. Mice with liver-specific Hmgb1-deficiency display exacerbated liver steatosis and hepatic insulin resistance when subjected to a high-fat diet or after fasting/refeeding. Global transcriptome and functional analysis revealed that the deletion of Hmgb1 gene enhances LXR activity resulting in increased lipogenesis. HMGB1 repression is not mediated through nucleosome landscape re-organization but rather via a preferential DNA occupation in region carrying genes regulated by LXR. Together these findings suggest that hepatocellular HMGB1 protects from liver steatosis development. HMGB1 may constitute a new attractive option to therapeutically target LXR axis during NAFLD.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.